Moleculin Biotech Inc. (NASDAQ: MBRX)
$4.39
+0.1640 ( +3.88% ) 41.4K
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Market Data
Open
$4.39
Previous close
$4.23
Volume
41.4K
Market cap
$9.82M
Day range
$3.94 - $4.45
52 week range
$3.22 - $15.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 43 | Jun 18, 2024 |
8-k | 8K-related | 22 | Jun 14, 2024 |
8-k | 8K-related | 16 | May 16, 2024 |
8-k | 8K-related | 17 | May 15, 2024 |
8-k | 8K-related | 42 | May 14, 2024 |
8-k | 8K-related | 16 | May 13, 2024 |
8-k/a | 8K-related | 16 | May 13, 2024 |
10-q | Quarterly Reports | 54 | May 10, 2024 |
8-k | 8K-related | 16 | May 09, 2024 |
8-k | 8K-related | 17 | May 08, 2024 |